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1. Introduction
Sarcoidosis is a chronic systemic disorder of an unknown etiology and it is characterized by
the presence of noncaseating granulomas in multiple organs. The granulomatous leison
affected by sarcoidosis is marked by the accumulation and activation of CD4+ helper T (Th)
cells with the Th1 phenotype and monocytes/macrophages, which suggest that a Th1-type
immune response plays a dominant role in the disease pathogenesis [1]. For example, the
important roles for IFN-γ and IL-12 were found in sarcoid lung [2], and a genome-wide gene
expression analysis of sarcoid lund tissues identified signal transducer and activator of
transcription-1 gene (STAT1) as one of the dominant network genes most highly expressed in
the sarcoidosis group [3].
IFN-α is known to be a potent stimulator of Th1 immune response, and increased type I IFN
signaling has been implicated in a number of autoimmune diseases such as systemic lupus
erythematosus (SLE) [4]. On the other hand, type I IFN has been used to treat a variety of
diseases, including chronic hepatitis C (HCV) infection. However, due to its immunomedu‐
latory effects, it has also been reported to induce several autoimmune and/or inflammatory
disorders [5]. Notably, an increasing number of sarcoidosis has been reported in chronic HCV
patients who received type I IFN therapy [6, 7]. In some cases, the sarcoid lesions improved
following dose reduction or cessation of the therapy, suggesting the importance of type I IFN
in the disease development. Moreover, from a genetic standpoint, we recently showed an
association between polymorphisms in the IFNA gene and susceptibility to sarcoidosis [8].
Another recent study found that in an European-American population, serum type I IFN
activity was higher in sarcodosis cases as compared to matched controls [9]. In addition,
besides IFN-induced sarcoidosis, a dozen case reports of sarcidosis have also been reported in
patients treated with tumor necrosis factor (TNF) antagonists [10]. A cross-regulation between
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type I IFN and TNF-α pathways has been proposed recently. This review focuses on a potential
role of these cytokines, type I IFN and TNF-α, in the pathogenesis of sarcoidosis.
2. Cross-regulation between type I IFN and TNF-α
TNF is a pivotal pro-inflammatory cytokine produced by macrophages, activated T cells,
natural killer cells and mast cells, it can also be produced by other non-immune cells such as
endothelial cells or stromal cells [11]. Type I IFNs (IFN-α and IFN-β) can be produced by almost
every cell type, including leukocytes, fibroblasts and endothelial cells and exert antiviral and
multiple immunomodulatory activities [12].
It  is  well  accepted that  TNF plays  a  critical  role  in  the  pathogenesis  of  certain  autoim‐
mune diseases such as rheumatoid arthritis (RA), whereas there is growing evidence that
IFN-α plays a pivotal role in another set of autoimmune diseases such as SLE [13].  The
elevated levels of type I IFN activity in SLE patient sera has been confirmed in the 1980s
[14, 15], and it was subsequently shown that overexpression of type I IFN-induced genes,
called IFN signature, was a common dominant pattern in human SLE [16]. The role of type
I IFN in SLE was further confirmed in the studies demonstrating induction of lupus-like
disease during IFN therapy [17].
Recently, anti-TNF agents are found to be associated with the development of drug-induced
lupus (DIL) as well. Indeed, a titer of anti-dsDNA antibodies has been found up to 15% of RA
patients on anti-TNF therapy [18]. Postmarketing studies on the three anti-TNF drugs have
suggested an estimated incidence of DIL of 0.1-0.4% (about 0.2%) [19, 20]. Another intriguing
side effect of TNF blockade is the induction of psoriasis-like disease in 3 to 5% of arthritis
patients without pre-existing psoriasis, which was also unexpected and paradoxical adverse
effect considering the excellent clinical response of psoriasis to TNF blockade [21]. This side
effect and the lupus-like syndrome observed in a part of patients undergoing therapy with
TNF antagonists led to us hypothesize that TNF might actually act as an antagonist of the type
I IFN pathway, further proposing cross-regulation between TNF-α and type I IFN [13].
What is the mechanism of cross-regulation between IFN-α and TNF-α pathways? Recent study
demonstrated that TNF regulates IFN-α production either by inhibiting the generation of
plasmacytoid dendritic cells (pDCs), a major producer of type I IFN, from CD34+ hematopoietic
progenitors in vitro or by inhibiting virus-induced IFN-α release by PBMCs. In addition,
neutralization of endogenous TNF sustained IFN-α secretion by pDCs [13]. Also, TNF can
induce the differentiation of the potent IFN-α-secreting immature pDCs to become mature
pDCs [22], which may cause downregulation of IFN-α production [23, 24]. These might explain
why a deficiency in TNF related to treatment with anti-TNF inhibitors can trigger a syndrome
that shares a number of features with SLE.
The relative balance between IFN-α and TNF-α has been also studied genetically and ethni‐
cally. In the study showing serum levels of TNF-α and IFN-α in sarocoidosis, significant
differences in cytokine levels were found between sarcoidosis patients of different ancestral
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backgrounds [9]. In this study, African-Americans had higher TNF-α levels than European-
American patients or matched controls, and patients with neurologic disease had significantly
higher TNF-α than patients lacking this manifestation. In a European-American population,
serum type I IFN activity was higher in sarcoidosis cases as compared to matched controls,
and patients with extra-pulmonary disease represented a high serum IFN group [9]. This study
demonstrated ancestral and subphenotype correlations with serum cytokine levels in patients
with sarcoidosis. On the other hand, however, in patients with SLE, serum TNF-α levels were
high in many SLE patients, and the high serum TNF-α levels were positively correlated with
high serum IFN-α levels across different ancestral backgrounds [25]. A genetic association
study demonstrated that the PTPN polymorphism was associated with skewing of cytokine
profiles toward higher IFN-α activity and lower TNF-α levels in vivo in patients with SLE.
Moreover, in untreated patients with juvenile dermatomyositis (JDM), serum IFN-α levels was
shown to be associated with the TNF-α G-308A promoter polymorphism [26]. In sarcoidosis,
the presence of a TNF-α -308A variant allele was also reported to be associated with the
susceptibility to and risk of sarcoidosis [27, 28].
While some studies suggest cross-regulation between IFN-α and TNF-α, not all studies of
autoimmune diseases fit this model. As in the example above, a positive correlation between
serum IFN-α and TNF-α in SLE was observed [25]. In JDM, the TNF-α -308A allele that has
been linked to higher TNF-α production [29] was associated with increased serum IFN-α levels
[26, 30]. In addition, besides known up-regulation of TNF-α in RA synovium, the increased
expression of type I IFN has been also reported in the synovium of patients with RA [31].
Therefore, it is likely that cross-regulation of IFN-α and TNF-α in humans may be more
complex.
In clinical settings, systemic juvenile arthritis treated with TNF antagonists display increased
transcription of IFN-α-regulated genes in their blood leukocytes compared with untreated
patients [13]. Further analysis revealed that infliximab (IFX) treatment induced an upregula‐
tion of the type I IFN genes in RA compared with untreated patients, whereas type I IFN
response genes were not affected in patients with a good response to TNF-α blockade [32]. In
addition, TNF-α blockade with etanercept (ETN), but not IFX, induced a persistent upregula‐
tion of type I IFN serum activity from 4 to 12 weeks of treatment in spondyloarthritis [33].
Similarly, in patients with Sjögren’s syndrome, a significant increase in IFN-α activity was
detected after treatment with ETN [34]. Meanwhile, in patients with inflammatory myopathies,
there was a significant increase in the type I IFN serum activity after IFX treatment without
any clinical improvement [35]. However, the relationship between type I IFN and TNF-α
appears to be complex and may be influenced by timing and disease progression.
Collectively, although there may exist the trend of a reciprocal regulation between type I IFN
and TNF-α in human autoimmunity, these studies as well as the cellular studies and experi‐
mental data indicate that the effect of TNF-α blockade on type I IFN is not universal and may
depend on the disease, the type of TNF-α blocker, as well as the clinical response to treatment
[11]. There are several hypothesis regarding cross-regulation between type I IFN and TNF-α.
The original hypothesis proposes that both cytokines can be regarded as opposite vectors and
both vectors are normally in balance. A shift towards the one arm may create a permissive
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environment for TNF-mediated inflammation (RA) or IFN-driven autoimmunity (SLE) [11].
Alternatively, type I IFN and IFN-α are influencing each other but the balance will be lost in
a pathological condition. In addition, an alternative hypothesis proposes that type I IFN plays
an important role in the initiation of autoimmunity, while the role of TNF-α increases during
the secondary effector phase of the disease [11].
3. Interferon-induced sarcoidosis
A cardinal feature of sarcoidosis is the presence of CD4+ T cells that interact with antigen-
presenting cells to initiate the formation and maintenance of glanulomas [36]. Activated
CD4+ cells differentiate into Th1-like cells and secrete predominantly IL-2 and IFN-γ. Such
cytokines maintain the activation of antigen-presenting cells such as macrophages and amplify
the local cellular immune response, establishing a vicious cycle that ultimately leads to the
formation of granulomas.
The first case of interferon-induced sarcoidosis (IIS) was reported in a patient treated with IFN-
β for advanced renal cell carcinoma in 1987 [37]. Since then, there has been an increasing
number of reports that supports a possible association between IFN therapy and the devel‐
opment or recurrence of sarcoidosis. Although the incidence of IIS is not known, the prevalence
of sarcoidosis in IFN-treated HCV patients has been reported to be rare range from 0.09% to
0.44% [38, 39]. The precise prevalence of IIS, however, may be underestimated and difficult to
assess because its clinical presentation mimics the constitutional IFN-related adverse effects
[6]. Actually, Hoffman et al. found a 5% incidence of sarcoidosis in a cohort of 60 patients who
participated in a randomized trial of IFN-α therapy for chronic HCV [40]
Basically the clinical presentation of IIS resembles that of its idiopathic counterpart. The most
commonly affected sites of involvement in IIS are skin and lungs, though many other organ
systems have also been involved such as liver, joints and heart. The lungs are the most frequent
organ affected in IIS (70%), similar but not as high as the incidence reported in typical
sarcoidosis (90%). The most frequent symptoms are dry cough and dyspnea. The second major
organ is the skin. The incidence of skin involvement appears to be much higher that reported
in natural sarcoidosis (60% versus 25%) [6, 38, 41]. The most common skin manifestation is
subcutaneous nodules, whereas erythema nodosum, reported to be the most common
cutaneous manifestation in typical sarcoidosis, is less frequently observed in IIS. On the basis
of the reported cases, IIS with cutaneous involvement can be expected to resolve within
approximately 6 months of treatment discontinuation. Its onset may vary from 2 weeks to 3
years after beginning of treatment. Men and women are equally affected [42, 43], and the mean
age of patients was approximately 50 years [39]. The majority (roughly two-thirds) of cases of
IIS arise during the first 6 months of IFN therapy, but clinical manifestations may also appear
after discontinuation of the antiviral treatment [38].
The pathophysiology of IIS is still unclear, but enhancement of Th1 immune response by type
I IFNs may play a crucial role. IFN-α has been shown to promote overexpression of MHC class
II antigens as well as upregulation of pro-inflammatory cytokines release by APCs and to
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stimulate monocytes to release IL-12. Furthermore, IFN-α, together with IL-12, can induce the
expression of the IL-12 receptor (IL-12R) β2 chain after antigen triggering [44]. In contrast to
asthma, T cells in bronchoalveolar lavage fluid in sarcoid lungs express a functional IL-12
receptor composed of both the β1 and β2 subunits [45], suggesting a role of IFN-α in sarcoid
pathogenesis. So, type I IFN stimulates the differentiation of Th1-type lymphocytes and
reduction of the activation of Th2 lymphocytes, favoring the formation of granuloma in
susceptible patients. However, among IIS, when compared to IFN-α therapy, IFN-β-accosiated
sarcoidosis is relatively rare [46].
The causal link between type I IFN and sarcoidosis is strengthened by the temporal relation‐
ship between IFN therapy and appearance of sarcoidosis, by the remission with therapy
cessation, and by the recurrence of symptoms on rechallenge with IFN. The occurrence of
sarcoidosis during monotherapy for diseases other than chronic hepatitis also supports this
relationship. Another recent study found that in an European American population, serum
IFN-α activity was higher in sarcoidosis cases as compared to matched controls [9].
Of patients with IIS, the majority of individuals (approximately 80%) received therapy for
chronic HCV infection, while sarcoidosis has also developed in association with the manage‐
ment of hepatitis B infection, multiple sclerosis, hematological and other malignant diseases.
To date, more than 80 patients cases of sarcoidosis that occurred in association with IFN-α
therapy for chronic HCV have been reported [47]. Similar to other species of viruses and
bacteria implicated in the etiology of sarcoidosis [48], some reports have suggested a potential
role for the HCV itself in the development of sarcoidosis [38, 49-51]. As chronic HCV infection
is associated with induction/stimulation of type 1 cellular immune response causing chronic
liver damage [52] as well as various immunological diseases [53-56], it is possible that the
antigenicity and viral persistence can serve as a trigger factor for the development of clinical
sarcoidosis in susceptible individuals [6]. IFN-α may act as an exacerbationg factor in this
situation.
Peginterferon (plus ribavirin) has recently been used to treat HCV infection. Pegylated IFN-
α is the result of adding a polyethylene glycol (Peg) moiety to the standard IFN-α molecule.
This modification reduces the clearance rate of the protein from the blood and extends the half-
time of IFN-α, providing a constant viral suppression which entails a more sustained virolog‐
ical response [57]. Ribavirin, a synthetic guanosine analogue, has been successfully used in
conjunction with peginterferon in the treatment of chronic HCV infection due to its ability to
inhibit RNA viral replication [58]. Although no cases of sarcoidosis that occurred with ribavirin
monotherapy have been reported, ribavirin might be a contributory factor in the development
of sarcoidosis via inhibiting Th2 cytokine response, and preserving or enhancing the Th1
immune reaction [59, 60]. This may explain why combination therapy with IFN-α and ribavirin
is more efficacious in treating HCV and, conversely, why it also may further predispose
patients to immunological disorders such as sarcoidosis [42]. Thus, enhanced clinical efficacy
of peginterferon plus ribavirin possibly results from the skewing Th1 response, favoring the
appearance of IIS with a greater likelihood than with conventional IFN-α (61).
Most patients with IIS had resolution of their disease without immunosuppressive treatment.
Half of the cases in the literature report spontaneous remission, over the course of a few
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months, after stopping IFN without further therapy. There are even some reports of remission
despite continuing IFN therapy. There was, however, a report showing that approximately
11% of cases, usually those with extracutaneous involvement, can have a chronic course and
6% may even reactivate after an initial improvement [38].
From a genetic stand of view, we previously showed an association between a polymorphism
in the IFN-α gene (IFNA), namely IFNA17, and susceptibility to sarcoidosis in the Japanese
population [8]. Then, we identified 2 major haplotype of the IFN-α gene and found that an
IFNA allele, overrepresented in patients with sarcoidosis, was subsequently associated with
increased IFN-α and IL-12 production in vitro [8]. Moreover, in a recent reported case of IIS,
HLA typing was performed and revealed that the patient was positive for HLA-DRB1*03 and
HLA-DQB1*02 [62], which have a correlation with the disease course or prognosis in sarcoi‐
dosis [63-65]. The authors hypothesized that this HLA profile predisposed the patient to IIS
development [62].
In summary, the immunopathogenesis of sarcoidosis is not fully understood, but it is likely
that the T cell response is biased toward a Th1 phenotype. To date, many cases of IIS have been
reported, suggesting a relationship between sarcoidosis and IFN therapy in patients with a
variety of diseases, especially chronic HCV infection. In addition to this, many lines of evidence
support the idea that IFN-α appears to play a role in the pathogenesis of sarcoidosis by
promoting Th1 immune response.
4. Anti-TNF-associated sarcoidosis
In the recent decades, TNF-α antagonists have made significant therapeutic milestones in the
treatment of various inflammatory diseases such as RA, psoriasis, and inflammatory bowel
disease. It has been suggested that CD4+ T-helper 1 cells and alveolar macrophages, which
secrete IFN-γ and TNF-α, play a pivotal role in the induction and maintenance of sarcoid
granuloma [66, 67]. Because of this, it has been postulated that TNF antagonists could be useful
for the treatment of granulomatous diseases like sarcoidosis. Indeed, in a multicenter random‐
ized double-blind placebo controlled study of IFX in 138 patients with chronic sarcoidosis, the
efficacy of IFX was confirmed [68]. Moreover, case series with a total of 50 patients reported a
positive treatment outcome with IFX in different type of sarcoidosis [69]. In contrast, the
soluble TNF receptor ETN failed to show therapeutic efficacy in both an open-label trial in
progressive pulmonary sarcoidosis and a double-blind randomized trial in refractory chronic
ocular sarcoidosis [69-71].
On  the  other  hand,  there  are  increasing  cases  of  acute  sarcoidosis  and  sarcoid-like
granulomatosis in patients treated with anti-TNF blocking agents have been reported. The
frequency of this adverse effect was roughly estimated to be at least 0.04% (1/2800] [72],
and this complication has been described in all three major anti-TNF blocking agents (IFX,
ETN, and adalibumab), which suggests a class effect [10]. However, while ETN account‐
ed for 27% of patient years of exposure to all three anti-TNF agents as of 2009, it represent‐
ed  61%  of  case  reports  of  anti-TNF-induced  sarcoidosis  at  that  time,  suggesting  some
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predilection for granuloma formation with this  drug [73].  Other studies also suggest  an
increased risk of sarcoidosis in patients treated with ETN compared to the other two agents
[74,  75].  Therefore,  it  is  intriguing that  ETN appeared to be more commonly associated
with this complication than other anti-TNF drugs and, meanwhile, to be less efficacious in
sarcoidosis treatment [70, 71].
The underlying diseases in cases of anti-TNF-associated sarcoidosis include RA, psoriasis/
psoriatic arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, and Crohn’s disease
[19, 76]. The time between initiation of therapy and the onset of signs and symptoms of
sarcoidosis in highly variable, with a median duration of approximately 21 months, a range <
1 month to 4 years [76]. Like IIS cases, the clinical picture of this type of sarcoidosis included
predominantly pulmonary and cutaneous features. Pulmonary involvement was found in 74%
patients, and cutaneous involvement in 29% [76].
The prognosis of sarcoidosis occurring during TNF blockade is generally favorable since
almost all patients showed clinical recovery after anti-TNF discontinuation with or without
corticosteroid therapy [75, 76]. Therapy with TNF antagonist was discontinued, resulting
in  spontaneous  resolution  in  some  patients,  whereas  symptoms  persisted  in  others,
necessitating corticosteroid treatment (40-50%) [74, 75]. While in some patients recurrence
or  exacerbations  of  sarcoidosis  after  switching to  a  different  TNF antagonist  have  been
reported, other patients were able to switch to a different TNF inhibitor without experienc‐
ing recurrences or exacerbations [72, 76].
The pathogenic mechanisms involved in the appearance of sarcoid granulomatosis in patients
treated with TNF antagonists are unclear. In addition, there could be notable differences
regarding risk of this complication among anti-TNF drugs. Although all the anti-TNF drugs
exert their action through blocking TNF-α, they have important differences in their structure
and pharmacokinetics, which could explain, in part, the differences that can be observed in
clinical efficacy as well as adverse effects, including the risk of granulomatous infections [77].
IFX and adalimumab (ADA) are monoclonal TNF-α antibodies whereas ETN is a TNF-α p75
soluble receptor. ETN binds mainly to soluble TNF-α molecules and interacts with transmem‐
brane TNF with reduced avidity compared with IFX, which binds both transmembrane and
soluble TNF. Clearance of ETN is 13 times greater than that of IFX and ADA. Therefore,
suppression of TNF-α is greater and more prolonged with IFX and ADA. IFX, therefore,
completely neutralizes TNF bioactivity, whereas freely diffusing ETN might be considered to
redistribute bioavailable TNF from sites of production to other sites of lower concentration
[77]. Also ETN, unlike IFX, does not produce cell lysis, therefore the inhibition of TNF would
not be enough to preserve the formation of the granuloma.
Furthermore, a recent study suggested that regulatory T (T reg) cells isolated from patients
with active RA were functionally defective in their ability to suppress cytokine production as
well as to convey suppressive phenotype to CD4+ effector T cells [78]. Another study showed
that sarcoidosis T reg cells, which is globally amplified in circulationg blood and BALF of
patients, completely inhibit IL-2 production of CD4+CD25- cells, but not that of IFN-γ or TNF-
α, suggesting the insufficient ability of sarcoid T reg cells to control local inflammation [79].
Treatment with IFX can restore the number and function of T reg cells [78]. Thus, treatment
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with IFX strongly inhibits TNF-α activity, leading to a restoration of T reg cell-mediated
inflammatory suppression. In contrast, low levels of TNF-α can persist after treatment with
ETN, hence T reg cells may remain down-regulated to some extent and can lead to an sustained
Th1 response. Moreover, enhanced IL-17A expression in sarcoid granulomas and in circulating
memory T cells from sarcoidosis patients was recently reported [80]. There is a report showing
that Th17 responses were inhibited by T reg cells from RA patients responding to the anti-TNF
antibody ADA, whereas there was no alteration in T reg number, function or phnotype in ETN
treated patients [81].
As previously noted, physiological crosstalk between TNF-α and IFN-α pathways has been
reported. There are some indications that type I IFN activity is upregulated during treatment
with TNF antagonists in some patients with inflammatory or autoimmune disease [13, 34].
IFN-α can enhance the production of IFN-γ and IL-2, expression levels of both cytokines are
elevated in sarcoid T cells [67]. As IFN-γ along with TNF-α is strongly implicated in granuloma
formation, the increased production of IFN-γ seen in some patients undergoing anti-TNF
therapy [76, 82, 83] may contribute to the development of sarcoid-like granulomatosis.
Actually, monoclonal anti-TNF-α antibodies can raise the Th1/Th2 ratio in the peripheral blood
[83, 84]. Thus, anti-TNF therapies can modulate the cytokine environment and may restore a
Th1 response. IFX and ADA inhibit T cell activation and IFN-γ production, whereas ETN does
not [85]. ETN even can enhance T cell production of IFN-γ [84, 86]. This fact could partially
explain the greater incidence of sarcoidosis with ETN compared with monoclonal antibody.
It is interesting to note that sarcoid-like granulaoma preferentially developed in the skin and
lungs, which are in direct contact with exogenous antigen. Several lines of evidence support
the idea that sarcoidosis results from exposures to possible environmental agents such as
Mycobacterium tuberculosis (M. tuberculosis) and Propionibacterium acnes (P. acnes) [87-89]. M.
tuberculosis or P. acnes associated with anti-TNF treatment was also reported [90, 91]. Anti-TNF
drugs are known to decrease antigenic clearance and increase infections. Then, mechanisms
involved in granulomatosis development during anti-TNF therapy could include increased
susceptibility to infection and modification of the cytokine environment and cellular recruit‐
ment within the tissues [72]. Among ant-TNF drugs, several studies indicate that infection with
granulomatous pathogens such as M. tuberculosis, histoplasmosis, and coccidioidomycosis
occur with 2-10-fold greater frequencies in patients treated with IFX than in those treated with
ETN [85, 92-94]. Additionally, in most cases of Listeria monocytogenes infection during treatment
with anti-TNF agent, IFX or ETN, patients had received IFX [95]. Both IFN-γ and TNF-α are
essential for protection against tuberculosis. The higher risk of such intracellular granuloma‐
tous pathogens that IFX poses than does ETN is therefore possibly due to the simultaneous
suppression of TNF-α and IFN-γ, and may as well explain why IFX, but not ETN, is effective
in treatment of sarcoidosis, where the presense of both IFN-γ and TNF-α is necessary.
Together, the development of sarcoid-like granulomatosis during therapy with TNF antago‐
nist is paradoxical in view of the central role of TNF-α in the formation and maintenance of
granulomas. There seems to be significant differences between the 2 classes of TNF antagonists
in the risk of this complication with the greater incidence of a soluble TNF receptor ETN-
associated sarcoidosis. Anti-TNF monoclonal antibody IFX or ADA can suppress TNF-α as
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well as IFN-γ and inhibit Th1 (and Th17) response partially through restoring the number and
function of T reg cells. IFX and ADA may also eliminate activated T cells and monocyte/
macrophage directly either by cell lysis or by inducing apoptosis [96]. On the contrary, ETN
therapy may result in an insufficient inhibition of TNF bioactivity and may enhance Th1
response with IFN-γ production causing the formation of the granuloma.
5. Conclusion
Type I IFN and TNF-α are cytokines with important roles in coordinating immune reactions
and potentially appear to contribute to the local and systemic inflammatory processes
underlying sarcoidosis pathogenesis. The increasing case reports of interferon-induced and
TNF-associated sarcoidosis support this idea. A cross-regulation between type I IFN and TNF-
α has been proposed in some autoimmune or inflammatory disorders. However, the studies
in patients with sarcoidosis show that there is not necessarily a direct balance between the
levels of type I IFN and TNF-α, and that the type of clinical manifestations, the disease phase,
and patient heterogeneity may contribute to create a complex picture. Ancestral background
as well as genetic polymorphisms may influence each cytokine level and clinical manifesta‐
tions, which can cause heterogeneous phenotype of the disease. Further work regarding
sarcoidosis induced by the cytokine/anti-cytokine therapy as well as clinical and in vitro studies
in sarcoidosis will help evaluate and treat these patients properly depend on the disease
phenotype and disease activity in the future.
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